We focus on “hard targets” in cancer and autoimmune disease with strong biological validation that have not been successfully drugged
We deploy our proprietary Rational Antibody Discovery platform to discover and engineer precision therapies, unlocking the therapeutic potential of these targets
Pipeline & Partners
Hummingbird Bioscience Announces US FDA Clearance of IND for First-in-Human Phase 1...
13 September 2021
Hummingbird Bioscience Strengthens Leadership Team with Appointment of Josh House as Chief...
01 September 2021